Teresa Carvalho, MS,  science writer—

Seelos Therapeutics has finished enrolling patients in its Phase 2/3 clinical trial of SLS-005 to treat amyotrophic lateral sclerosis (ALS), the company announced. The ongoing trial (NCT05136885) recruited 160 patients with familial and sporadic ALS, and top-line results are expected by the second half of…

A large Phase 3 trial designed to confirm the safety and efficacy of the approved therapy Relyvrio (sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) is now fully enrolled. Amylyx Pharmaceuticals announced the completion of patient recruiting for the trial, called PHOENIX (NCT05021536), which will…

uniQure has entered an agreement to acquire the full rights to Apic Bio‘s investigational gene therapy APB-102, which is being developed for amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations. uniQure now is planning to start a Phase 1/2 clinical trial of APB-102 later this year. Under the…

Neopharm has acquired exclusive rights to commercialize AMX0035 (sodium phenylbutyrate and taurursodiol) in Israel, Gaza, the West Bank, and to the Palestinian Authority as a treatment of amyotrophic lateral sclerosis (ALS). The company’s agreement with Amylyx Pharmaceuticals makes it responsible for the distribution and marketing of AMX0035…

An oral suspension form of Radicava (edaravone), an approved treatment of amyotrophic lateral sclerosis (ALS), was favored for patient reimbursement in Canada by a branch of the Canadian Agency for Drugs and Technologies in Health (CADTH). The opinion issued by the CADTH Canadian Drug Expert Committee recommended that Radicava Oral…

Health Canada asked more information regarding masitinib as a potential add-on therapy for amyotrophic lateral sclerosis (ALS) before continuing to review a request for its approval. AB Science, masitinib’s developer, now has 90 consecutive days to reply to the notice of deficiency issued by Health Canada, given…

Radicava Oral Suspension, an oral formulation of edaravone, has been approved in Canada for treating amyotrophic lateral sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA), the subsidiary of Mitsubishi Tanabe Pharma America that markets Radicava in Canada, has announced plans to make the oral formula available to patients…

High total protein levels in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — are linked to shorter survival among amyotrophic lateral sclerosis (ALS) patients with limb-onset disease, a study showed. The researchers noted a similar association was found for high CSF…

Seelos Therapeutics is planning to launch an expanded access program (EAP) that gives people with amyotrophic lateral sclerosis (ALS) who are not eligible for clinical trials the opportunity to access the company’s investigational therapy SLS-005. The program will be conducted in collaboration with the Sean M. Healey &…

Cytokinetics has launched its fifth annual Communications Grant Program to support patient advocacy groups working with amyotrophic lateral sclerosis (ALS) and other communities. A total of five $20,000 grants will be given to winning organizations to help them improve their outreach and patient engagement. The deadline for applications…